Nadine Cerf-Bensussan, MD, PhD

INSERM UMR1163, Laboratory of Intestinal Immunity
Paris France
Biographical Sketch: Dr. Cerf-Bensussan earned her medical degree and Master of Immunology in 1981 from Institut Pasteur and the University of Paris. She earned her PhD in 1987 at the University of Paris. From 1987-1995 she held a tenure position as Chargé de Recherche (CR1) at INSERM, and from 1995-1997 she was Research Director at INSERM and Hôpital Necker in Paris. From 1998 to present she has been the Head of Laboratory of Intestinal Immunity. Dr. Cerf-Bensussan is the recipient of many awards, including the Prix Charles Debray (1990), the Prix Rosa Lamarca (2001), the Chevalier de la Légoin d’Honneur (2013) and the ERC Advanced Grant (2014-2019). She has 160 publications in PubMed, 189 in the Web of Science and 7,892 citations. She serves on several scientific boards, including the Board Research Federation Necker, the Board of the International Society for Research on Celiac Disease and as a director on the Board of Institut Imagine. She has been the organizer of two scientific congresses, including the 10th International Congress on Celiac Disease in Paris in June 2002, and the 15th International Congress of Mucosal Immunology in Paris in July 2011.

Any personal financial relationships? No

I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.

I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.

I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.

I agree to provide educational content and resources in advance for review if requested by ICMI.

If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.

If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

To the best of my ability, I will ensure that any speakers or content I suggest is independent of commercial bias.

I will recuse myself from planning activity content in which I have a conflict of interest.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 06/30/2015 by Nadine Cerf-Bensussan

Papers:
T Cells
T.123 IL-15 AND NOTCH DRIVE THE DIFFERENTIATION OF A NEW SUBSET OF GUT INNATE LYMPHOID CELLS
W.122 The Gut Symbiont Segmented Filamentous Bacteria: cultivation and host response in an in vitro co-culturing system

	I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.
	I will include, as the first slide of any presentation, a full disclosure of any financial relationships that may influence my presentation.
	The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.
	I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.
	I agree to provide educational content and resources in advance for review if requested by ICMI.
	If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
	If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
	To the best of my ability, I will ensure that any speakers or content I suggest is independent of commercial bias.
	I will recuse myself from planning activity content in which I have a conflict of interest.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".